Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Your research
Source: nct - Country: Poland,Netherlands,Canada,Russian Federation,United States,Australia,United Kingdom,France,Argentina,Germany
nct
Update Il y a 5 ans
Open-Label Tolvaptan Study in Subjects With ADPKD
To demonstrate whether tolvaptan modifies ADPKD progression as measured by changes from baseline (from trial 156-04-251) in total kidney volume (TKV) and renal function.
Country
Argentina
,
Australia
,
Belgium
,
Canada
,
France
,
Germany
,
Italy
,
Netherlands
,
Poland
,
Romania
,
Russian Federation
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
Vicente Torres, MD, PhD
Update Il y a 5 ans
Tolvaptan Phase 3 Efficacy and Safety Study in ADPKD
This study's purpose is to evaluate the long-term safety and efficacy of tolvaptan versus placebo in patients with ADPKD.
Country
Argentina
,
Australia
,
Belgium
,
Canada
,
Denmark
,
France
,
Germany
,
Italy
,
Japan
,
Netherlands
,
Poland
,
Romania
,
Russian Federation
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy
This is a Phase 3, multi-national, open-label, 2-arm randomized study in patients with surgically incurable metastatic melanoma who have received no prior chemotherapy, or biochemotherapy for the treatment of metastatic disease. The primary objective of this trial is to compare overall survival for patients with advanced melanoma who are randomized to receive CP-675,206 with that of patients who are randomized to receive either dacarbazine or temozolomide (investigator choice)
Country
Argentina
,
Australia
,
Austria
,
Belgium
,
Canada
,
France
,
Germany
,
Greece
,
Israel
,
Italy
,
Mexico
,
Netherlands
,
Poland
,
Russian Federation
,
Slovakia
,
South Africa
,
Spain
,
Sweden
,
Switzerland
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
1